Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
Listed Dossiers
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Acetate, Goserelin
2. Goserelin
3. Ici 118630
4. Ici-118630
5. Ici118630
6. Zoladex
1. 145781-92-6
2. Fertilan
3. Zoladex
4. Goserelin (acetate)
5. Goserelin Acetate [jan]
6. 6yuu2pv0u8
7. Dsstox_cid_26736
8. Dsstox_rid_81865
9. Dsstox_gsid_46736
10. 1-9-luteinizing Hormone-releasing Factor (swine), 6-(o-(1,1-dimethylethyl)-d-serine)-, 2-(aminocarbonyl)hydrazide, Acetate (salt)
11. Cas-145781-92-6
12. Ici-118630 Acetate
13. Unii-6yuu2pv0u8
14. Novgos
15. Zoladex La
16. Zoladex (tn)
17. Ncgc00167588-02
18. Ncgc00183275-01
19. Schembl6094
20. Goserelin Acetate (jan/usp)
21. Chembl1200501
22. Dtxsid9046736
23. Goserelin Acetate [vandf]
24. Goserelin Acetate [mart.]
25. Glxc-26187
26. Goserelin Acetate [usp-rs]
27. Goserelin Acetate [who-dd]
28. Tox21_112579
29. Tox21_112937
30. Bdbm50247974
31. Hy-13673a
32. Ici118630
33. Mfcd01747329
34. Cs-4509
35. Goserelin Acetate [orange Book]
36. (d-ser(tbu)6,azagly10)-lhrh Acetate
37. Goserelin Acetate [usp Monograph]
38. D00573
39. 781g926
40. Goserelin Acetate, >=99% (hplc), White Powder
41. Q27265738
42. Goserelin, European Pharmacopoeia (ep) Reference Standard
43. H-pyr-his-trp-ser-tyr-d-ser(tbu)-leu-arg-pro-nhnhconh2 Acoh
44. Goserelin Acetate, United States Pharmacopeia (usp) Reference Standard
45. Goserelin For Nmr Identification, European Pharmacopoeia (ep) Reference Standard
46. 6-[o-(1,1-dimethylethyl)-d-serine]-1-9-luteinizing Hormone-releasing Factor (swine) 2-(aminocarbonyl)hydrazide Acetate (salt)
Molecular Weight | 1329.5 g/mol |
---|---|
Molecular Formula | C61H88N18O16 |
Hydrogen Bond Donor Count | 18 |
Hydrogen Bond Acceptor Count | 18 |
Rotatable Bond Count | 32 |
Exact Mass | 1328.66256879 g/mol |
Monoisotopic Mass | 1328.66256879 g/mol |
Topological Polar Surface Area | 533 Ų |
Heavy Atom Count | 95 |
Formal Charge | 0 |
Complexity | 2590 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35689
Submission : 2024-05-07
Status : Active
Type : II
NDC Package Code : 55463-0005
Start Marketing Date : 2003-11-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.
GDUFA
DMF Review : Reviewed
Rev. Date : 2020-03-12
Pay. Date : 2019-11-29
DMF Number : 34363
Submission : 2019-12-19
Status : Active
Type : II
Certificate Number : R1-CEP 2003-037 - Rev 03
Issue Date : 2020-12-18
Type : Chemical
Substance Number : 1636
Status : Valid
Registration Number : 304MF10160
Registrant's Address : Hauptstrasse 144,4416 Bubendorf Switzerland
Initial Date of Registration : 2022-12-23
Latest Date of Registration : --
NDC Package Code : 55463-0005
Start Marketing Date : 2003-11-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31488
Submission : 2017-04-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 31489
Submission : 2017-04-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29713
Submission : 2015-09-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17768
Submission : 2004-10-18
Status : Inactive
Type : II
Certificate Number : R1-CEP 2005-276 - Rev 02
Issue Date : 2017-01-31
Type : Chemical
Substance Number : 1636
Status : Withdrawn by Holder
Certificate Number : R1-CEP 2007-183 - Rev 01
Issue Date : 2014-06-12
Type : Chemical
Substance Number : 1636
Status : Valid
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?